Pfizer-Lilly Endeavor Shows NGF Inhibitor Tanezumab Lowers Osteoarthritic Pain

When the FDA accepted tanezumab, a nerve growth factor inhibitor developed jointly by Pfizer and Eli Lilly, for a Biologics License Application (BLA) review in March, the monoclonal antibody was heralded as a potential first-in-class treatment for patients with moderate to severe osteoarthritis who experienced inadequate relief from other analgesics.